SCHEMBL9952841

SCHEMBL9952841

CCC(=O)C(O)C(O)CO

nearest known ligand 0.41

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 0.41
LMNA P02545 3/20 0.38
L3MBTL1 Q9Y468 1/20 0.36
TDP1 Q9NUW8 4/20 0.35
USP2 O75604 1/20 0.33
SLCO1B1 Q9Y6L6 1/20 0.33
OR51E2 Q9H255 1/20 0.32
FFAR3 O14843 1/20 0.32
ALDH1A1 P00352 1/20 0.32
KDM4E B2RXH2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14639994 1.00 PDE4A (0.41) PDE4ALMNAL3MBTL1TDP1USP2
SCHEMBL13879019 0.85 PDE4A (0.48) PDE4ALMNAL3MBTL1TDP1USP2
SCHEMBL15239580 0.85 PDE4A (0.48) PDE4ALMNAL3MBTL1TDP1USP2
SCHEMBL8971728 0.85 PDE4A (0.48) PDE4ALMNAL3MBTL1TDP1USP2
SCHEMBL27845927 0.85 PDE4A (0.48) PDE4ALMNAL3MBTL1TDP1USP2
SCHEMBL14411835 0.85 PDE4A (0.48) PDE4ALMNAL3MBTL1TDP1USP2
SCHEMBL8095380 0.83 PDE4A (0.58) PDE4ALMNAL3MBTL1TDP1USP2
SCHEMBL343766 0.83 PDE4A (0.58) PDE4ALMNAL3MBTL1TDP1USP2
SCHEMBL13998446 0.83 PDE4A (0.58) PDE4ALMNAL3MBTL1TDP1USP2
SCHEMBL4160010 0.83 PDE4A (0.58) PDE4ALMNAL3MBTL1TDP1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119424690-A Electronegativity-adjustable contrast agent film forming agent composition, contrast agent and preparation method thereof 北京大学 2025-02-14 CN claimed
US-20260028406-A1 NANOBODY BASED IMAGING AND TARGETING OF ECM IN DISEASE AND DEVELOPMENT MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2026-01-29 US disclosed
CN-119424690-A Electronegativity-adjustable contrast agent film forming agent composition, contrast agent and preparation method thereof 北京大学 2025-02-14 CN disclosed
US-20240327493-A1 PD-1 AGONIST GEORGE MASON UNIVERSITY 2024-10-03 US disclosed
CN-103261430-A Targeted perhydrolases DU PONT 2013-08-21 CN disclosed
CN-101558161-B Production of peracids using enzymes having perhydrolysis activity DU PONT 2013-05-01 CN disclosed
CN-102906256-A Process for purification of proteins DU PONT 2013-01-30 CN disclosed
WO-2012087790-A1 PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY E.I. DUPONT DE NEMOURS AND COMPANY (US) 2012-06-28 WO disclosed
CN-102264894-A Enzyme catalyzed peracid generating formulation 2011-11-30 CN disclosed
CN-101300333-B Enzymatic production of peracids from carboxylic acid ester substrates using non-heme haloperoxidases E. I. DU PONT DE NEMOURS AND CO. (US) 2011-11-30 CN disclosed
CN-102177234-A control of enzymatic peracid production DU PONT 2011-09-07 CN disclosed
CN-102168114-A Enzymatic production of peracids from carboxylic acid ester substrates using non-heme haloperoxidases DU PONT 2011-08-31 CN disclosed
CN-101970674-A Production of peracids using enzymes having perhydrolytic activity DU PONT 2011-02-09 CN disclosed
CN-101864155-A Resin composition, molding thereof and process for producing the resin composition SONY CORP 2010-10-20 CN disclosed
CN-101558161-A Production of peracids using enzymes having perhydrolysis activity DU PONT (US) 2009-10-14 CN disclosed
CN-101300333-A Enzymatic production of peracids from carboxylic acid ester substrates using non-heme haloperoxidases DU PONT (US) 2008-11-05 CN disclosed
CN-101283100-A Enzymatic production of peracids using lactobacilli having perhydrolysis activity DU PONT (US) 2008-10-08 CN disclosed
CN-1914266-A Resin composition, shaped article using such resin composition and method for producing resin composition SONY CORP (JP) 2007-02-14 CN disclosed
CN-1914278-A Resin composition, molded article thereof, and method for producing the resin composition SONY CORP (JP) 2007-02-14 CN disclosed
US-RE28729-E Process for synthesizing specific complete mixed polyol esters THE PROCTER & GAMBLE COMPANY (US) 1976-03-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260028406-A1 NANOBODY BASED IMAGING AND TARGETING OF ECM IN DISEASE AND DEVELOPMENT VSIG8, VSIR, IGLV6-57 PDE4A 1891/4885LMNA 1407/4885L3MBTL1 633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.